GMAB: Genmab A/S ADS Stocks News on April 6, 2025

GMAB

Insider Monkey

4 days ago

Is Genmab A/S (GMAB) d The Most Profitable Biotech Stock To Buy Right Now?

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

GMAB

GlobeNewswire

5 days ago

Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

GMAB

Insider Monkey

5 days ago

Is Genmab A/S (GMAB) the Most Undervalued Healthcare Stock to Buy According to Analysts?

GMAB

MT Newswires

6 days ago

Genmab Says European Commission Grants Marketing Authorization for Tivdak as Cervical Cancer Treatment

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

GMAB

Business Wire

6 days ago

TIVDAK® (tisotumab vedotin) Approved by European Commission for Previously Treated Recurrent or Metastatic Cervical Cancer

Transactions in connection with share buy-back program

GMAB

GlobeNewswire

6 days ago

Transactions in connection with share buy-back program

Genmab’s Tivdak approved in Japan for advanced cervical cancer

GMAB

Pharmaceutical Technology

9 days ago

Genmab’s Tivdak approved in Japan for advanced cervical cancer

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

GMAB

Benzinga

10 days ago

Japanese Drug Regulator Approves Genmab Cancer Drug For Patients With Advanced Cervical Cancer

GMAB

MT Newswires

10 days ago

Genmab Says Japan Approves Tivdak for Cervical Cancer

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

GMAB

Business Wire

10 days ago

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and Welfare for the Treatment of Advanced or Recurrent Cervical Cancer that has Progressed on or after Chemotherapy

Genmab Announces Initiation of Share Buy-Back Program

GMAB

GlobeNewswire

12 days ago

Genmab Announces Initiation of Share Buy-Back Program

GMAB

MT Newswires

13 days ago

Genmab Denies Trade Secret Misappropriation Claims by AbbVie

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

GMAB

GlobeNewswire

15 days ago

Genmab to Vigorously Defend Alleged Claims of Trade Secret Misappropriation by AbbVie Inc.

GMAB

Insider Monkey

18 days ago

Genmab A/S (GMAB): A Bull Case Theory

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

GMAB

GlobeNewswire

20 days ago

Investigational Rinatabart Sesutecan (Rina-S®) Continues to Show Encouraging Antitumor Activity in Patients with Advanced Ovarian Cancer

GMAB

GlobeNewswire

25 days ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

GMAB

GlobeNewswire

25 days ago

Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab

Passing of Genmab A/S’ Annual General Meeting

GMAB

GlobeNewswire

25 days ago

Passing of Genmab A/S’ Annual General Meeting

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

GMAB

BioPharma Dive

25 days ago

A new obesity biotech launches; Gilead plans to quickly advance once-yearly PrEP for HIV

Genmab says J&J not exercising option on HexaBody-CD38

GMAB

TipRanks

a month ago

Genmab says J&J not exercising option on HexaBody-CD38

GMAB

MT Newswires

a month ago

William Blair Upgrades Genmab to Outperform From Market Perform

GMAB

Investing.com

a month ago

Genmab sinks as J&J opts not to develop Darzalex successor; stock upgraded

GMAB

MT Newswires

a month ago

RBC Cuts Price Target on Genmab to DKK2,300 From DKK2,400, Keeps Outperform Rating

GMAB

MT Newswires

a month ago

Truist Lowers Price Target on Genmab to $45 From $50, Maintains Buy Rating

GMAB

MT Newswires

a month ago

Genmab Says Johnson & Johnson Declines Global License Option for HexaBody-CD38; Shares Fall

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

GMAB

Business Wire

a month ago

Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

GMAB

Insider Monkey

a month ago

Is Genmab A/S (GMAB) the Best Cash-Rich Undervalued Stock to Invest In?

GMAB

GlobeNewswire

a month ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

GMAB

GlobeNewswire

a month ago

Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

GMAB

GlobeNewswire

a month ago

Grant of Restricted Stock Units to Management and Employees and Grant of Warrants to Employees in Genmab

GMAB

Insider Monkey

a month ago

Genmab A/S (GMAB): Among the Stocks That Will Go to the Moon According to Analysts

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GMAB

GlobeNewswire

a month ago

Capital Increase in Genmab as a Result of Employee Warrant Exercise

GMAB

Insider Monkey

a month ago

Is Genmab (GMAB) One of the Best Growth Stocks to Invest In According to Analysts?

GMAB

MT Newswires

a month ago

Genmab Gets Japanese Regulatory Approval for Follicular Lymphoma Drug

$EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma$

GMAB

GlobeNewswire

a month ago

EPKINLY® (epcoritamab) Approved by Japan Ministry of Health, Labour and Welfare for Additional Indication as a Treatment for Relapsed or Refractory Follicular Lymphoma

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

GMAB

GlobeNewswire

2 months ago

Genmab to Participate in a Fireside Chat at the 45th Annual TD Cowen Health Care Conference

GMAB

Insider Monkey

2 months ago

Why Genmab (GMAB) and Sonic Automotive (SAH) Are Advancing Today

GMAB

MT Newswires

2 months ago

Leerink Upgrades Genmab to Outperform From Market Perform, Price Target is $27

Notice to Convene the Annual General Meeting of Genmab A/S

GMAB

GlobeNewswire

2 months ago

Notice to Convene the Annual General Meeting of Genmab A/S

GMAB

GuruFocus.com

2 months ago

Genmab AS (GMAB) Q4 2024 Earnings Call Highlights: Robust Revenue Growth and Strategic ...

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

GMAB

GlobeNewswire

2 months ago

Genmab Files Annual Report with the U.S. Securities and Exchange Commission

GMAB

GlobeNewswire

2 months ago

Genmab Publishes 2024 Annual Report

GMAB

Insider Monkey

2 months ago

Why Genmab A/S (GMAB) Is Among the Best Healthcare Stocks To Buy According to Analysts

Exploring High Growth Tech Stocks In February 2025

GMAB

Simply Wall St.

2 months ago

Exploring High Growth Tech Stocks In February 2025

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GMAB

GlobeNewswire

2 months ago

Grant of Restricted Stock Units and Warrants to Employees in Genmab

GMAB

Insider Monkey

2 months ago

Is Genmab (GMAB) the High Growth International Stock to Invest in Now?

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

GMAB

GlobeNewswire

2 months ago

Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2024

GMAB

Zacks

3 months ago

GMAB vs. QGEN: Which Stock Is the Better Value Option?

GMAB

Zacks

3 months ago

Genmab (GMAB) Upgraded to Buy: Here's What You Should Know

GMAB

Zacks

3 months ago

Are Investors Undervaluing Genmab (GMAB) Right Now?

High Growth Tech Stocks To Watch In January 2025

GMAB

Simply Wall St.

3 months ago

High Growth Tech Stocks To Watch In January 2025

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

GMAB

GlobeNewswire

3 months ago

Genmab to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

GMAB

GlobeNewswire

4 months ago

Genmab to Hold 2024 R&D Update and ASH Data Review Meeting

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

GMAB

GlobeNewswire

4 months ago

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

GMAB

Business Wire

4 months ago

Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)

GMAB

MT Newswires

4 months ago

Genmab's Potential Leukemia Treatment Shows Overall Response Rate of 61% in Phase 1/2 Trial

Exploring None's High Growth Tech Stocks With Strong Potential

GMAB

Simply Wall St.

4 months ago

Exploring None's High Growth Tech Stocks With Strong Potential

$Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis$

GMAB

Business Wire

4 months ago

Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis

$Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)$